Back

Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review

Kapoor, K. M.; Kapoor, A.

2020-03-30 infectious diseases
10.1101/2020.03.24.20042366 medRxiv
Show abstract

BackgroundCoronavirus pandemic is currently a global public health emergency. At present, no pharmacological treatment is known to treat this condition, and there is a need to review the available treatments. ObjectiveWhile there have been studies to describe the role of chloroquine and hydroxychloroquine in various viral conditions, there is limited information about the use of them in COVID-19. This systematic review aims to summarize the available evidence regarding the role of chloroquine in treating coronavirus infection. MethodsThe preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were used for this review. A literature search was performed using PUBMED & Google Scholar to find articles about the role of CQ in COVID-19 patients. ResultsWe included 19 publications (Five published articles, three letters/correspondence, one commentary, five pre-proofs of accepted articles, one abstract of yet to be published article, and four were pre-prints (not yet peer-reviewed) articles) in this systematic review. All the articles mentioned about the role of chloroquine and /or hydroxychloroquine in limiting the infection with SARS-CoV-2 (the virus causing COVID-19). ConclusionsThere is theoretical, experimental, preclinical and clinical evidence of the effectiveness of chloroquine in patients affected with COVID-19. There is adequate evidence of drug safety from the long-time clinical use of chloroquine and hydroxychloroquine in other indications. More data from ongoing and future trials will add more insight into the role of chloroquine and hydroxychloroquine in COVID-19 infection.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 21%
8.5%
2
BMC Infectious Diseases
118 papers in training set
Top 0.3%
6.5%
3
Journal of Infection and Public Health
15 papers in training set
Top 0.1%
6.5%
4
International Journal of Antimicrobial Agents
15 papers in training set
Top 0.1%
6.4%
5
Journal of Medical Virology
137 papers in training set
Top 0.5%
4.9%
6
Frontiers in Pharmacology
100 papers in training set
Top 0.6%
4.4%
7
Scientific Reports
3102 papers in training set
Top 28%
4.2%
8
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 1%
3.3%
9
Cureus
67 papers in training set
Top 1%
3.1%
10
Frontiers in Medicine
113 papers in training set
Top 2%
2.9%
50% of probability mass above
11
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.1%
12
Annals of Translational Medicine
17 papers in training set
Top 0.5%
1.9%
13
Clinical Microbiology and Infection
60 papers in training set
Top 0.4%
1.9%
14
Contemporary Clinical Trials Communications
11 papers in training set
Top 0.2%
1.7%
15
PLOS Neglected Tropical Diseases
378 papers in training set
Top 3%
1.5%
16
Journal of Antimicrobial Chemotherapy
43 papers in training set
Top 0.3%
1.4%
17
Frontiers in Public Health
140 papers in training set
Top 6%
1.1%
18
BMC Medicine
163 papers in training set
Top 5%
1.1%
19
International Journal of Infectious Diseases
126 papers in training set
Top 3%
1.0%
20
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.4%
1.0%
21
JAMA Network Open
127 papers in training set
Top 4%
0.9%
22
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.9%
23
Trials
25 papers in training set
Top 1%
0.8%
24
Frontiers in Neurology
91 papers in training set
Top 5%
0.8%
25
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 2%
0.8%
26
eClinicalMedicine
55 papers in training set
Top 2%
0.8%
27
Journal of Clinical Virology
62 papers in training set
Top 0.7%
0.8%
28
National Science Review
22 papers in training set
Top 2%
0.8%
29
The Journal of Infectious Diseases
182 papers in training set
Top 5%
0.8%
30
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%